Evidence map›Paper›PMID 35733201›Full record

ArticleTrials2022

CANreduce-SP-adding psychological support to web-based adherence-focused guided self-help for cannabis users: study protocol for a three-arm randomized control trial.

J I Mestre-Pintó, F Fonseca, M P Schaub, C Baumgartner, M Alias-Ferri, M Torrens

Registry-linked trialOpen access · goldAbstract readClinical Trial Protocol
In one paragraph

Article in Trials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04517474 (Evaluación de Una Herramienta E-Salud Para la reducción Del Consumo de Cannabis), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04517474 naunknown statusnot on this map

Evaluación de Una Herramienta E-Salud Para la reducción Del Consumo de Cannabis

TypeinterventionalSponsorParc de Salut MarRan2020 to 2022Enrolled300ConditionsCannabis Use DisorderArmsCANreduce, psychological support
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Interpol review of forensic drug chemistry, 2022-2025.Forensic science international. Synergy · 2026
    Review
  2. Article
  3. Cannabis use disorder: an overview of treatment approaches in Europe.European archives of psychiatry and clinical neuroscience · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

J I Mestre-PintóAddiction Research Group (GRAd), Neuroscience Research Program, Hospital del Mar Medical Research Institute (IMIM), 08003, Barcelona, Spain. jmestre@imim.es.
F Fonseca *Addiction Research Group (GRAd), Neuroscience Research Program, Hospital del Mar Medical Research Institute (IMIM), 08003, Barcelona, Spain.
M P SchaubSwiss Research Institute for Public Health and Addiction, University of Zurich, Zurich, Switzerland.
C BaumgartnerSwiss Research Institute for Public Health and Addiction, University of Zurich, Zurich, Switzerland.
M Alias-FerriAddiction Research Group (GRAd), Neuroscience Research Program, Hospital del Mar Medical Research Institute (IMIM), 08003, Barcelona, Spain.
M TorrensAddiction Research Group (GRAd), Neuroscience Research Program, Hospital del Mar Medical Research Institute (IMIM), 08003, Barcelona, Spain.
Hospital del Mar Research Institute · ESUniversity of Zurich · CHPompeu Fabra University · ESUniversitat Autònoma de Barcelona · ES

Funding

Agència de Gestió d'Ajuts Universitaris i de Recerca AGAUR Gencat 2017 SGR 316Departament de Salut, Generalitat de Catalunya PERIS SLT006/17/00014Instituto de Salud Carlos III RD16/0017/0010
6 · The paper itself

Abstract

backgroundCannabis is the most-frequently used illicit drug in Europe. Over the last few years in Spain, treatment demand has increased, yet most cannabis users do not seek treatment despite the related problems. A web-based self-help tool, like CANreduce 2.0, could help these users to control their consumption.

methodsThis study protocol describes a three-arm randomized controlled trial (RCT) comparing the effectiveness of three approaches, in terms of reducing cannabis use among problematic cannabis users, the first two treatment arms including the Spanish version of CANreduce 2.0 (an adherence-focused, guidance-enhanced, web-based self-help tool) (1) with and (2) without psychological support; and the third group (3) treatment as usual (TAU). Study hypotheses will be tested concerning the primary outcome: change in the number of days of cannabis use over the previous week, comparing assessments at 6 weeks and 3 and 6 months follow-up between groups and against baseline. Secondary outcomes related to cannabis use will be tested similarly. Mental disorders will be explored as predictors of adherence and outcomes. Analyses will be performed on an intention-to-treat basis, then verified by complete case analyses. DISCUSSION: This study will test how effective the Spanish version of CANreduce 2.0 (CANreduce-SP) is at reducing both the frequency and quantity of cannabis use in problematic users and whether adding psychological support increases its effectiveness.

trial registrationThis trial is registered with the Clinical Trials Protocol Registration and Results System (PRS) number: NCT04517474 . Registered 18 August 2020, (Archived by archive.is https://archive.is/N1Y64 ). The project commenced in November 2020 and recruitment is anticipated to end by November 2022.

Indexed as

CannabisCounselingMarijuana AbusePatient Acceptance of Health CareHealth BehaviorHumansInternetMental DisordersRandomized Controlled Trials as TopicTreatment OutcomeAdherenceCannabis use disorderCANreduceCognitive behavioural therapyGuidancePsychological supportRandomized controlled trialReducing cannabisSelf-help tool

Identifiers

PMID35733201
PMCPMC9214682
OpenAlexW4283372230

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.